| |
|
total |
EBV reactivation |
|
univariate |
| N = |
116 |
18 |
(16.4%) |
|
| Sex |
M |
71 |
13 |
(18.3%) |
p=0.180 |
| F |
45 |
5 |
(11.1%) |
|
| median age (range) |
|
49,8 (17,6-70,6) |
48,5(17,6-68,5) |
|
p=0.445 |
| Stemcell source |
cordblood |
1 |
0 |
(0.0%) |
p=1.000 |
| peripheral blood |
106 |
17 |
(16.0%) |
|
| bonemarrow |
9 |
1 |
(11.1%) |
|
| Donor |
Related |
35 |
1 |
(2.9%) |
p=0.015 |
| Unrelated |
81 |
17 |
(21.0%) |
|
| HLA mismatch |
|
20 |
6 |
(30.0%) |
p=0.561 |
| Conditioning |
NMA |
106 |
15 |
(14.2%) |
p=0.359 |
| |
MA |
10 |
3 |
(30.0%) |
|
| ATG |
|
87 |
18 |
(20.7%) |
p=0.004 |
| EBV serology (R/D) |
+/+ |
94 |
18 |
(19.1%) |
p=0.429 |
| aGVHD |
|
64 |
12 |
(18.8%) |
p=1.000 |
Abbreviations: HLA:Human Leukocyte Antigen; NMA:Non Myeloablative; MA:Myeloablative; ATG:Anti-Thymocyte Globulin; EBV: Epstein-Barr Virus; R/D:Recipient/Donor.
Comparison between reactivation and no reactivation group: Fisher’s Exact test. |
|
